The text starts here.

News Release

FOR IMMEDIATE RELEASE
April 24, 2001

EISAI CO., LTD. AND NEUROGENETICS, INC. SIGN AGREEMENT

Eisai Co., Ltd.
Public Relations Department
81-3-3817-5120

Neurogenetics, Inc.
Scott A. Rieger
Principal
Strategic Investor Relations, Inc.
(858) 578-2910


EISAI CO., LTD. AND NEUROGENETICS, INC. SIGN AGREEMENT

Tokyo, Japan and La Jolla, California, April 24, 2001 -- Eisai Co., Ltd., (President & CEO: Haruo Naito) and Neurogenetics Inc. (Chairman: Dr. William T. Comer) today announced the signing of an exclusive agreement involving Alzheimer's disease targets utilizing human genetics. Under the agreement, Neurogenetics has granted to Eisai rights of first negotiation to collaborate on selected Alzheimer's disease drug discovery programs. Financial terms of the agreement were not disclosed.


Eisai Co., Ltd. is a research-based human health care company, which discovers, develops and markets products in more than 30 countries. Eisai is a global leader in Alzheimer's disease research and treatment. AriceptR, a symptomatic Alzheimer's disease treatment launched by Eisai in the United States in 1997, is currently sold in more than 50 countries with over 450 million days of patient use worldwide. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. For additional information, visit Eisai's web site at http://www.eisai.co.jp.


Neurogenetics, Inc., founded in April 2000, is a La Jolla-based emerging biopharmaceutical company focused on the development of novel small molecule therapeutics for Alzheimer's disease and related neurodegenerative disorders including Lou Gehrig's disease (ALS), Huntington's disease, Parkinson's disease, spongiform encephalopathies, stroke, and epilepsy. The Company has exclusive license agreements with Massachusetts General Hospital for a number of significant discoveries. Neurogenetics' efforts include the establishment of novel molecular targets through large-scale analysis of disease-specific genetic polymorphisms for prevalent neurodegenerative diseases. The Company's drug development activities focus on creating orally active small molecule therapeutics to halt the progress of such diseases through interactions with these targets. For more information, visit Neurogenetics Inc.'s web site at http://www.neurogeneticsinc.com.